Panbela Therapeutics, a clinical-stage biopharmaceutical company, filed a prospectus supplement on May 15, 2024, to update and supplement information in a previous prospectus dated June 24, 2022. The supplement includes the company's quarterly report filed with the SEC on the same date. The prospectus relates to the issuance of up to 2,433,789 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.4408 per share as of May 14, 2024. The supplement and the attached quarterly report provide updated financial data, including a net loss of $7.1 million for the quarter ended March 31, 2024, and a decrease in cash and cash equivalents from $2.578 million to $262,000. The company has incurred...Show More

Panbela Therapeutics, a clinical-stage biopharmaceutical company, filed a prospectus supplement on May 15, 2024, to update and supplement information in a previous prospectus dated June 24, 2022. The supplement includes the company's quarterly report filed with the SEC on the same date. The prospectus relates to the issuance of up to 2,433,789 shares of common stock underlying previously issued warrants. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.4408 per share as of May 14, 2024. The supplement and the attached quarterly report provide updated financial data, including a net loss of $7.1 million for the quarter ended March 31, 2024, and a decrease in cash and cash equivalents from $2.578 million to $262,000. The company has incurred losses of $132.6 million since its inception and continues to face a high degree of risk, as detailed in the 'Risk Factors' section. The quarterly report also outlines the company's reliance on third-party CROs for clinical trials, with a recent notification from the CRO of their intent to terminate the relationship if unpaid balances are not settled, potentially delaying trials.